I'm staying flexible. The RBL's and SME's will formulate the protocols with the best strategy. I think we may even see a tweak in what the phase design will be. Like possibly a P2/2b, they would know the best way to proceed and present to the FDA. And if the science warrants, based on everything we already know from data it could be designed to go straight into a P3.
I'm also thinking we'll know a LOT more by mid/late August.

So, while I'm still accumulating I'm pretty much sitting back and waiting for the fireworks. Letting the science speak for itself.